Ebola Virus Drug Development Pipeline Expands with Contributions from 18+ Key Companies | DelveInsight New York, USA, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ebola Virus Drug Development Pipeline Expands with Contributions from 18+ Key Companies | DelveInsight The Ebola virus market is focused on...

BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines WASHINGTON, D.C. and ROME, Italy, May 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and...

GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports ATLANTA, GA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its manuscript entitled “A...

AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) -- AbCellera announced today successful completion of its first antibody discovery partnership with MassBiologics of the University...

MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Company plans on granting royalty-free licenses to universities interested in using the...